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Abstract
The human MxA protein is part of the antiviral state induced by alpha/beta interferon (IFN-alpha/beta).
MxA inhibits the multiplication of several RNA viruses in cell culture. However, its antiviral potential
in vivo has not yet been fully explored. We have generated MxA-transgenic mice that lack a functional
IFN system by crossing MxA-transgenic mice constitutively expressing MxA with genetically targeted
(knockout) mice lacking the beta subunit of the IFN-alpha/beta receptor (IFNAR-1(-/-) mice). These
mice are an ideal animal model to investigate the unique antiviral activity of human MxA in vivo,
because they are unable to express other IFN-induced proteins. Here, we show that MxA confers
resistance to Thogoto virus, La Crosse virus, and Semliki Forest virus. No Thogoto virus progeny was
detectable in MxA-transgenic mice, indicating an efficient block of virus replication at the primary site
of infection. In the case of La Crosse virus, MxA restricted invasion of the central nervous system. In
contrast, Semliki Forest virus multiplication in the brain was detectable in both MxA-expressing and
nonexpressing IFNAR-1(-/-) mice. However, viral titers were clearly reduced in MxA-transgenic mice.
Our results demonstrate that MxA does not need the help of other IFN-induced proteins for activity but
is a powerful antiviral agent on its own. Moreover, the results suggest that MxA may protect humans
from potential fatal infections by La Crosse virus and other viral pathogens.
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The human MxA protein is part of the antiviral state induced by alpha/beta interferon (IFN-a/b). MxA
inhibits the multiplication of several RNA viruses in cell culture. However, its antiviral potential in vivo has
not yet been fully explored. We have generated MxA-transgenic mice that lack a functional IFN system by
crossing MxA-transgenic mice constitutively expressing MxA with genetically targeted (knockout) mice lacking
the b subunit of the IFN-a/b receptor (IFNAR-12/2 mice). These mice are an ideal animal model to investigate
the unique antiviral activity of human MxA in vivo, because they are unable to express other IFN-induced
proteins. Here, we show that MxA confers resistance to Thogoto virus, La Crosse virus, and Semliki Forest
virus. No Thogoto virus progeny was detectable in MxA-transgenic mice, indicating an efficient block of virus
replication at the primary site of infection. In the case of La Crosse virus, MxA restricted invasion of the
central nervous system. In contrast, Semliki Forest virus multiplication in the brain was detectable in both
MxA-expressing and nonexpressing IFNAR-12/2 mice. However, viral titers were clearly reduced in MxA-
transgenic mice. Our results demonstrate that MxA does not need the help of other IFN-induced proteins for
activity but is a powerful antiviral agent on its own. Moreover, the results suggest that MxA may protect
humans from potential fatal infections by La Crosse virus and other viral pathogens.
La Crosse virus (LACV) and closely related viruses of the
California serogroup of bunyaviruses (family, Bunyaviridae)
infect humans in many countries of the northern hemisphere
(4, 13). LACV is the most important arboviral cause of pedi-
atric encephalitis in the United States. From 1996 to 1997, a
total of 252 cases of LACV encephalitis have been reported
(5). It has been estimated that there may be as many as 300,000
LACV infections annually in the midwestern United States
alone (4). However, the vast majority of infections is clinically
inapparent or associated with mild symptoms, suggesting that
humans have a powerful defense against LACV infections.
It is well known that the interferon (IFN) system plays a
pivotal role in the first line of defense against viruses. Many
cell types produce and secrete alpha and beta IFN (IFN-a/b)
in response to viral infections in a paracrine fashion, thereby
signalling the presence of an invading virus to neighboring
cells. The binding of IFN-a/b to their specific cell surface
receptors triggers the intracellular Jak/STAT pathway, leading
to the activation or enhanced expression of more than 50 genes
(34, 37, 38). Their combined activities generate a so-called
antiviral state. The proper functioning of the IFN-a/b system is
essential for the survival of certain viral infections. Blocking
IFN-a/b activity in mice by the injection of antibodies directed
against IFN-a and IFN-b leads to a dramatically increased
sensitivity to many viruses (14, 15, 17). Furthermore, geneti-
cally targeted (knockout) mice lacking the b subunit of the
IFN-a/b receptor (IFNAR-12/2 mice) are unable to establish
an antiviral state and, as a consequence, are highly susceptible
to many viral infections, despite the presence of an otherwise
intact immune system (6, 28). However, the contribution of an
individual IFN-induced protein to the generation of the anti-
viral state is difficult to assess, because various effector proteins
appear to have overlapping antiviral activities (38).
Mx proteins are among the few effector proteins of the
IFN-a/b system with known antiviral activity. They are highly
conserved large GTPases with homology to dynamin and have
been found in all vertebrate species investigated so far, includ-
ing mammals, birds, and fish (reviewed in references 3 and 41).
The human MxA protein is a cytoplasmic protein (1, 40) which
is rapidly induced in response to acute viral infections (33).
Transfected cells, expressing MxA under the control of a con-
stitutive promoter, are resistant to infections with viruses of
several RNA virus families, namely, Orthomyxoviridae (10, 11,
30, 31), Paramyxoviridae (35, 36, 44), Rhabdoviridae (31), Bu-
nyaviridae (9, 25), and Togaviridae (27). A first indication for
the role of MxA in vivo came from transgenic mice which
constitutively express human MxA but lack functional mouse
Mx proteins (29). These MxA-transgenic mice were completely
resistant to infections with Thogoto virus (THOV), a tick-
borne orthomyxovirus, and they proved to be less sensitive to
infections with influenza A virus and vesicular stomatitis virus
(29).
Here, we demonstrate that the function of a single IFN-
induced effector protein can be studied in vivo without inter-
ference from activities of other IFN-induced proteins. To that
end, we crossed MxA-transgenic and IFNAR-12/2 mice result-
ing in MxA1/1 IFNAR-12/2 mice. We show that MxA expres-
sion is sufficient to protect IFNAR-12/2 mice against a lethal
challenge dose of THOV. Furthermore, enhanced resistance
was observed against LACV and Semliki Forest virus (SFV), a
neurotropic virus of the family Togaviridae.
* Corresponding author. Mailing address: Institute of Medical Vi-
rology, University of Zu¨rich, Gloriastrasse 30, CH-8028 Zu¨rich, Swit-
zerland. Phone: 41-1-634 26 56. Fax: 41-1-634 49 06. E-mail: pavlovic
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MATERIALS AND METHODS
Mice. The generation of the MxA-transgenic mouse lines L and G, as well as
the generation of IFNAR-12/2 knockout mice, was described previously (28, 29).
MxA-expressing IFNAR-12/2 knockout mice that originated from the MxA-
transgenic L line were generated as follows. Mice homozygous for the MxA
transgene (MxA1/1) were mated with IFNAR-12/2 mice. Resulting F1 offspring
(MxA1/2 IFNAR-11/2) were interbred. The IFNAR-1 genotype of the F2 gen-
eration was analyzed by PCR as described previously (28). To test whether F2
animals were homozygous for the MxA transgene, they were backcrossed with
BALB/c mice, and the MxA genotypes of the progeny were analyzed by PCR as
described previously (28). Mice homozygous for both MxA and the IFN-a/b
receptor defiency (MxA1/1 IFNAR-12/2) were used for further breeding. A
second MxA-transgenic IFNAR-12/2 mouse line was generated with the MxA-
transgenic G line. For unknown reasons, breeding of MxA-transgenic mice of
line G never yielded homozygous females (29). Therefore, male mice homozy-
gous for MxA of line G were first crossed with female IFNAR-12/2 mice. F1
animals thereof were interbred, and the resulting F2 progeny were tested for
their MxA and IFNAR-1 genotypes as described above. F2 males homozygous
for the MxA transgene as well as the IFN-a/b receptor deficiency (MxA1/1
IFNAR-12/2) were selected and backcrossed with IFNAR-12/2 mice. The re-
sulting offspring (MxA1/2 IFNAR-12/2) were used for virus challenge experi-
ments. All mouse lines described in this paper have mutations in the endogenous
mouse Mx genes Mx1 and Mx2 (39, 42). As a consequence, functional Mx1 and
Mx2 proteins are not expressed in these mice.
Analysis of MxA expression in transgenic mice. Animals were anesthetized
and exsanguinated, and a variety of organs and tissue samples were removed,
snap frozen in liquid nitrogen, and stored at 270°C. The frozen samples were
homogenized in a buffer containing 50 mM Tris-HCl (pH 8.3), 50 mM KCl, 5
mM MgCl2, 1 mM EDTA, and 0.1% Triton X-100. Subsequently, the cells were
lysed by sonication. The lysates were cleared by centrifugation at 10,000 3 g for
10 min and mixed with sodium dodecyl sulfate (SDS)-gel sample buffer (26).
Protein samples (20 mg per lane) were separated by SDS–10% polyacrylamide
gel electrophoresis. Transfer to nitrocellullose membranes (Millipore, Bedford,
Mass.) and Western blot analysis were carried out essentially as previously
described (1), with a monoclonal antibody specific for MxA (21) and a chemi-
luminescence detection kit (Pierce, Rockford, Ill.).
Virus stocks. The Sicilian (SiAr126) isolate of THOV (2) was grown in
BALB/c mice as previously described (19). Stock virus prepared from liver
homogenates contained 7 3 106 PFU per ml as titrated on Swiss mouse 3T3 cells.
The original strain of LACV (43) was grown on baby hamster kidney (BHK-21)
cells yielding a titer of 1.2 3 108 50% tissue culture infective doses (TCID50) per
ml as determined on Vero cells. The SFV prototype strain was grown on Swiss
mouse 3T3 cells yielding a titer of 6.8 3 109 TCID50 per ml as determined on the
same cell type.
Experimental viral infections. For each set of experiments mice were age
matched. Five- to eight-week-old mice were anesthetized and intraperitoneally
infected with 300 PFU of THOV, 105 TCID50 of LACV, or 102 TCID50 of SFV.
The animals were monitored for clinical symptoms at least once a day.
Detection of virus yields. Mice were anesthetized and exsanguinated, and
organs and tissue samples were removed, snap frozen in liquid nitrogen, and
stored at 270°C. The frozen samples were weighed and transferred to a vial
containing 9 volumes of phosphate-buffered saline (PBS) solution per weight of
tissue sample. The organs were ground with quartz sand, and the resulting
suspensions were cleared by centrifugation and again frozen at 270°C. Virus
yields were determined by the TCID50 method with Swiss mouse 3T3 cells for
THOV and SFV and Vero cells for LACV.
Immunohistochemical analysis. Mouse brains were fixed in PBS containing
4% formaldehyde for 48 h and subsequently washed in PBS. Coronal and sagital
slices of approximately 3 mm were dehydrated through graded alcohols and
embedded in paraffin. Sections of 3-mm nominal thickness were stained with
hematoxylin and eosin or stained for cellular and viral proteins. Immunostaining
for the glial fibrillary acidic protein (GFAP) was carried out with a rabbit
antiserum specific for GFAP (DAKO, Copenhagen, Denmark) and a biotinyl-
ated swine anti-rabbit immunoglobulin serum (dilution, 1:300 and 1:250, respec-
tively). Visualization was achieved by using avidin-peroxidase and diaminoben-
zidine. For the immunostaining of MxA a mouse monoclonal antibody specific
for MxA and polyclonal rabbit anti-mouse immunoglobulin serum was used
(dilution, 1:50 and 1:20, respectively). Visualization was carried out by using calf
intestinal alkaline phosphatase complexed with a mouse monoclonal anti-alka-
line phosphatase antibody (dilution, 1:50). Immunostaining of viral antigens was
performed with a polyclonal rabbit anti-C protein of SFV (dilution, 1:50) and a
polyclonal rabbit antiserum specific for the nucleocapsid protein of LACV (di-
lution, 1:50) (kindly provided by Raju Ramasamy, Meharry Medical College,
Nashville, Tenn.). Mouse monoclonal anti-rabbit immunoglobulins (dilution,
1:25) and a rabbit polyclonal anti-mouse immunoglobulin (dilution, 1:25) were
used as bridging antibodies. The remaining steps of the procedure were the same
as those used for the immunostaining of MxA. The secondary and tertiary
antibodies were purchased from DAKO. All immunostained sections were coun-
terstained with hematoxylin.
RESULTS
Generation of MxA-transgenic mice lacking a functional
IFN-a/b receptor. We have previously generated two MxA-
transgenic mouse lines, designated G and L (29). The expres-
sion of the transgene is controlled by the 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase gene promoter (12), resulting
in an IFN-independent constitutive expression of MxA in var-
ious organs (29).
To generate transgenic mice which express MxA but lack a
functional IFN-a/b receptor, we crossed transgenic L mice
homozygous for MxA (MxA1/1) and knockout mice homozy-
gous for IFN-a/b receptor deficiency (IFNAR-12/2) (28). An-
imals of the resulting F1 generation were interbred, and the
genotype of the F2 generation was analysed. Subsequently,
MxA1/1 IFNAR-12/2 mice of the F2 generation were used to
breed the F3 generation. If not indicated otherwise, homozy-
gous MxA1/1 IFNAR-12/2 mice derived from line L were
used for all challenge experiments described in this study.
The expression of MxA was verified by Western blot analysis
of protein extracts from various organs of an MxA-transgenic
IFNAR-12/2 mouse with a monoclonal antibody specific for
the MxA protein (21). Figure 1 shows that MxA is detectable
in all tissues but muscles. The highest expression levels were
found in the brain and spleen, as previously noted in mice of
the parental L line (29).
Human MxA confers complete resistance to THOV in IF-
NAR-12/2 knockout mice. To test whether MxA is able to
reverse the virus-sensitive phenotype of mice lacking a func-
tional IFN system, MxA-transgenic mice and appropriate con-
trol animals were infected with THOV, a tick-borne ortho-
myxovirus that causes lethal infections in mice lacking
functional mouse Mx alleles (19). However, THOV is ex-
tremely sensitive to the antiviral action of MxA in cell cultures
(10) and in vivo (29). Mice of the genotypes MxA1/1 IFNAR-
11/1, MxA1/1 IFNAR-12/2, MxA2/2 IFNAR-12/2, and
MxA2/2 IFNAR-11/1 were infected intraperitoneally with 300
PFU of THOV. All MxA-transgenic mice survived the chal-
lenge, irrespective of whether the animals were deficient for
the IFN-a/b receptor or not (Fig. 2A). In contrast, mice lack-
ing the MxA transgene succumbed to infection within 3 days
(IFNAR-12/2 mice) or 5 days (IFNAR-11/1 mice) (Fig. 2A).
In parallel, we monitored the multiplication of THOV in two
additional mice per group. These animals were sacrificed 36 h
after infection, and their livers were removed. Upon intraperi-
toneal inoculation, THOV is known to infect the liver and to
replicate to high titers in this organ (7, 19). As expected, liver
homogenates of animals without MxA exhibited high viral
yields exceeding 106 TCID50 per g of tissue. In contrast, no
virus was detectable in MxA-transgenic mice (Fig. 2B). Taken
together, the data indicate that the expression of MxA in IF-
NAR-12/2 mice is sufficient to confer complete protection
against THOV infection.
FIG. 1. Detection of MxA protein by Western blot analysis. Various organs
and tissue samples from an adult MxA1/1 IFNAR-12/2 mouse (originating from
the MxA-transgenic L line) were collected, cell extracts were prepared, and
samples of 20 mg of protein per lane were separated by SDS-polyacrylamide gel
electrophoresis. MxA was detected with an MxA-specific monoclonal antibody
(21).
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Human MxA restricts multiplication of LACV in IFNAR-
12/2 knockout mice. Mice show a strong age-dependent sus-
ceptibility to LACV, whereby 6-week-old mice acquire com-
plete resistance (22, 23). However, we have recently observed
that adult IFNAR-12/2 knockout mice are highly susceptible
to experimental infections with LACV (20). LACV multipli-
cation has been shown to be inhibited by the antiviral activity
of MxA in Vero cells (9). To assess the activity of MxA on
LACV multiplication in vivo, we challenged adult MxA-trans-
genic IFNAR-12/2 and IFNAR-12/2 control mice with 105
TCID50 of LACV by the intraperitoneal route. As expected,
the infection of 6-week-old IFNAR-12/2 mice led to the de-
velopment of severe neurological symptoms and to the death
of 17 of 18 animals with a mean survival time of 6.5 days (Fig.
3A). In contrast, 7 of 16 MxA-transgenic IFNAR-12/2 mice
survived infection. The nine MxA-transgenic animals that died
showed an increased mean survival time of 8 days (Fig. 3A). To
corroborate these findings, we infected animals of another
MxA-transgenic IFNAR-12/2 mouse line which was generated
by using MxA-transgenic G mice. Again, all of the IFNAR-
12/2 control mice died after infection with LACV, whereas
four of seven MxA1/2 IFNAR-12/2 mice survived, although
they were heterozygous for the MxA transgene (data not
shown). All experimental infections with LACV were carried
out with approximately 10 50% lethal doses to assure 100%
killing of the IFNAR-12/2 mice. At lower virus doses, we
observed higher survival rates for both the MxA1/1 IFNAR-
12/2 mice and IFNAR-12/2 control mice (data not shown).
To investigate MxA-mediated inhibition of LACV in more
detail, three additional IFNAR-12/2 and two MxA-transgenic
IFNAR-12/2 mice were infected intraperitoneally with 105
TCID50 of LACV and sacrificed 6 days later. By that time, two
IFNAR-12/2 mice showed severe clinical symptoms including
complete paralysis of the hind legs. In the diseased IFNAR-
12/2 mice, high titers ($108 TCID50 per g of tissue) of LACV
were found in the brain (Fig. 3B, animals 3 and 4). The third
animal showed no clinical symptoms. Nevertheless, the brain
FIG. 2. MxA-transgenic IFNAR-12/2 mice are resistant to THOV infection.
(A) Adult mice of four different genotypes were challenged with THOV and
monitored for survival. MxA1/1 IFNAR-12/2 (n ), IFNAR-12/2 (h), MxA1/1
IFNAR-11/1 (F), and IFNAR-11/1 mice (E) were infected with 300 PFU of
THOV per ml by the intraperitoneal route. (B) Virus growth in livers of sus-
ceptible and resistant mice. Two animals per genotype were infected as described
above and sacrificed 36 h after infection. Their livers were removed and assayed
for infectivity. Each column represents the mean virus titer for two animals.
FIG. 3. Enhanced resistance of MxA-transgenic IFNAR-12/2 mice to LACV
infection. (A) Adult MxA1/1 IFNAR-12/2 (n ) and MxA2/2 IFNAR-12/2 (h)
mice were infected with 105 TCID50 of LACV by the intraperitoneal route and
monitored for survival. (B) Virus growth in brains of susceptible and resistant
mice. Two MxA1/1 IFNAR-12/2 mice (animals 1 and 2) and three MxA2/2
IFNAR-12/2 mice (animals 3, 4, and 5) were infected as described above and
sacrificed 6 days after infection. Tissue samples were removed and assayed for
infectivity.
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still contained 103 TCID50 of LACV per g of brain tissue (Fig.
3B, animal 5), indicating that the virus had started to multiply
in the central nervous system (CNS). In contrast, no virus was
detectable in the two MxA-transgenic IFNAR-12/2 mice (Fig.
3B, animals 1 and 2).
Brain tissues from the same mice were further analyzed by
histological and immunohistological methods. LACV multipli-
cation in the brains of IFNAR-12/2 mice lacking MxA was
confirmed by immunostaining the viral nucleocapsid protein
with specific antibodies (Fig. 4B). Furthermore, hematoxylin
and eosin staining (Fig. 4C) or immunostaining for GFAP (Fig.
4D) revealed infiltration of mononuclear inflammatory cells
and astrocytes characteristic of meningitis and pronounced
astrogliosis. In brains of healthy MxA-transgenic IFNAR-12/2
mice expressing MxA in the majority of cells (Fig. 4E), no signs
of virus infection and no mononuclear cell infiltrates were
detectable (Fig. 4F to H).
These results demonstrate that (i) IFNAR-12/2 mice are a
suitable animal model for studies on LACV-mediated patho-
genesis and (ii) human MxA is able to inhibit the multiplica-
tion of LACV in vivo. To investigate the cause of death of the
MxA-transgenic IFNAR-12/2 mice that developed clinical
symptoms and finally succumbed, we assessed virus replication
and pathology in the brain of one diseased animal of that
group. The animal clearly died from acute meningoencephali-
tis. The viral titer was determined to be 108 TCID50 per g of
FIG. 4. Histology and immunostaining of brain sections from an MxA1/1 IFNAR-12/2 and an MxA2/2 IFNAR-12/2 mouse. Both types of animals were infected
with 105 TCID50 of LACV by the intraperitoneal route. Mice were sacrificed 6 days after infection, and brain sections were prepared. Micrographs show the brain of
an IFNAR-12/2 mouse (panels A to D) and that of an MxA1/1 IFNAR-12/2 mouse (panels E to H) immunostained for MxA protein (panels A and E), the
nucleocapsid protein of LACV (panels B and F), or GFAP (panels D and H) or stained with hematoxylin and eosin (HE) (panels C and G).
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brain tissue, which is comparable to the titers observed in
brains of IFNAR-12/2 mice (Fig. 3B, animals 3 and 4). More-
over, immunohistochemical analysis revealed the accumulation
of LACV nucleocapsid protein, as well as infiltrates of lym-
phocytes and astrocytes (data not shown).
Human MxA restricts multiplication of SFV in IFNAR-12/2
knockout mice. Experimental infections of mice with SFV lead
to a wide range of pathologies depending on the virus strain
and the age of the host. For example, 129Sv mice survive high
doses of the SFV prototype strain without apparent clinical
symptoms (8). In contrast, adult IFNAR-12/2 mice are ex-
tremely sensitive to the prototype strain of SFV and are killed
upon inoculation with as few as 10 infectious particles (28). We
infected MxA-transgenic IFNAR-12/2 mice and IFNAR-12/2
control mice with 100 PFU of the prototype strain of SFV by
the intraperitoneal route. All 22 IFNAR-12/2 mice rapidly
exhibited severe neurological symptoms and died within 6 days,
as expected (Fig. 5A). In contrast, only a fraction (13 of 22) of
the MxA-transgenic animals developed disease and succumbed
to the infection (Fig. 5A). The surviving animals did not show
any clinical symptoms during an observation period of 30 days.
Furthermore, the mean survival time of diseased MxA-trans-
genic IFNAR-12/2 mice was increased compared to that of
IFNAR-12/2 mice (6.8 and 4.5 days, respectively). In an addi-
tional experiment, we infected MxA-transgenic IFNAR-12/2
mice derived from the G line. Six of fifteen MxA1/2 IFNAR-
12/2 mice and 0 of 14 IFNAR-12/2 control mice survived the
infection with 100 PFU of SFV (data not shown). All SFV
infections were carried out with approximately 10 50% lethal
doses to assure 100% killing of the IFNAR-12/2 control mice.
With less inoculum, we observed higher survival rates of both
MxA1/1 IFNAR-12/2 mice and control mice (data not
shown).
To examine SFV multiplication and pathology, two MxA-
transgenic IFNAR-12/2 mice and two IFNAR-12/2 control
mice were infected with SFV and sacrificed 4 days later (Fig.
5B). In IFNAR-12/2 mice virus replication occurred in all
organs of the mice tested. For example, up to 3 3 1010 TCID50
per g of tissue was observed in the brain (Fig. 5B). Organs of
MxA-transgenic IFNAR-12/2 mice contained drastically re-
duced viral titers ranging from 0.05% (brain) to 2% (lung) of
the corresponding titers in IFNAR-12/2 mice lacking MxA
(Fig. 5B). In parallel, brain sections were subjected to immu-
nohistological analysis (Fig. 6). Large amounts of the C protein
of SFV were found in the brains of IFNAR-12/2 mice (Fig.
6B). Staining with hematoxylin and eosin (Fig. 6C) and immu-
nostaining for GFAP (Fig. 6D) revealed an acute encephalo-
myelitis in IFNAR-12/2 mice. In contrast, viral antigens were
not detectable in the brains of healthy MxA-transgenic IF-
NAR-12/2 mice (Fig. 6F). Furthermore, no signs of encepha-
litis were found in the brains of these mice (Fig. 6G and H).
However, diseased MxA-transgenic IFNAR-12/2 mice accu-
mulated large amounts of SFV antigens in their brains and
showed the typical immunohistological picture of acute en-
cephalitis usually observed in SFV-infected IFNAR-12/2 con-
trol mice (data not shown). Evidently, SFV is able to overrun
the protective effect of MxA in some of the MxA-transgenic
IFNAR-12/2 mice.
These results demonstrate that MxA inhibits the multiplica-
tion of SFV in vivo. However, the death of some MxA-trans-
genic IFNAR-12/2 mice indicates that MxA expression was
not sufficient to block SFV replication completely.
DISCUSSION
Here, we show that human MxA protein protects MxA-
transgenic mice from lethal virus infection independent of
other IFN-induced proteins. We generated MxA-transgenic
IFNAR-12/2 mice because they express MxA constitutively in
various organs but are unable to mount an endogenous IFN-
a/b response. Challenge experiments revealed that these mice
were highly resistant to infection with THOV, a tick-borne
orthomyxovirus. We have previously shown that THOV is in-
hibited by MxA in transgenic mice (29). The previous experi-
ments were performed with inbred mouse strains that lack
functional mouse Mx proteins but possess an otherwise intact
IFN-a/b system. It was therefore possible that other IFN-
induced proteins would act in conjunction with ectopic MxA to
yield complete protection. The results presented here clearly
demonstrate that this is not the case. MxA alone is able to
block the multiplication of THOV without the help of other
IFN-induced proteins. Since antibodies against THOV have
been detected in the sera of various species including man (7),
one has to assume that human infections can occur but that the
virus may be completely inhibited by the action of human MxA
protein. Accordingly, only a few clinical cases due to THOV
virus infection in humans have been reported.
FIG. 5. Enhanced resistance of MxA-transgenic IFNAR-12/2 mice to SFV
infection. (A) Adult MxA1/1 IFNAR-12/2 (n ) and MxA2/2 IFNAR-12/2 (h)
mice were infected with 100 PFU of SFV by the intraperitoneal route and
monitored for survival. (B) Virus growth in various organs of susceptible and
resistant mice. Two MxA1/1 IFNAR-12/2 and two MxA2/2 IFNAR-12/2 mice
were infected as described above and sacrificed 4 days after infection. Tissue
samples were removed and assayed for infectivity. Each column represents the
mean virus titer for two animals.
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In cell cultures, MxA has the potential to inhibit a wide
range of RNA viruses, including members of the families Or-
thomyxoviridae, Paramyxoviridae, Rhabdoviridae, Bunyaviridae,
and Togaviridae (18). However, the crucial question about the
importance of MxA for the antiviral defense in vivo has re-
mained unanswered. LACV and closely related viruses fre-
quently infect humans (4, 13). In spite of the high number of
infections, clinical cases are rare. We and others have shown
previously that the multiplication of LACV and other mem-
bers of the family Bunyaviridae is inhibited by MxA in stably
transfected Vero cells (9, 25). These results suggested that
MxA is part of the antiviral defense mechanism against bun-
yaviruses in humans. However, experiments elucidating the
effect of MxA in vivo were not possible, because a suitable
animal model was missing. The laboratory mouse Mus muscu-
lus shows a strong age-dependent susceptibility to experimen-
tal LACV infections. Suckling mice die from infection irre-
spective of the site of virus inoculation, whereas adult mice
develop a lethal encephalitis only when infected by the intra-
cerebral route (22, 23). The known sensitivity of IFNAR-12/2
knockout mice to many viral infections (6, 28) prompted us to
test these mice for their susceptibility to LACV (20). Our
results demonstrate that adult IFNAR-12/2 mice indeed rep-
resent a suitable animal model for studies on LACV-mediated
pathogenesis. Interestingly, the neurological symptoms and
the immunohistological findings observed in LACV-infected
FIG. 6. Histology and immunostaining of brain sections from an MxA1/1 IFNAR-12/2 mouse and an MxA2/2 IFNAR-12/2 mouse. Both were infected with 100
PFU of SFV per ml by the intraperitoneal route. Mice were sacrificed 4 days after infection, and brain sections were prepared. Micrographs show the brain of an
MxA1/1 IFNAR-12/2 mouse (panels A to D) and that of an MxA2/2 IFNAR-12/2 mouse (panels E to H) immunostained for MxA protein (panels A and E), the
C protein of SFV (panels B and F), or GFAP (panels D and H) or stained with hematoxylin and eosin (HE) (panels C and G).
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IFNAR-12/2 mice resemble those described in rare cases of
acute LACV encephalitis in humans (24).
Here, we show that about 40% of the MxA-transgenic
IFNAR-12/2 mice survived the experimental infections with-
out apparent clinical symptoms while 100% of IFNAR-12/2
control mice died. Furthermore, MxA-transgenic animals that
succumbed to infection showed a delayed onset of disease. It is
presently not clear why only a subset of MxA-transgenic ani-
mals survived. The extent to which virus growth was blocked by
MxA in muscle cells, the major extraneuronal replication site
(16), may be critical to the course of the disease. For unknown
reasons, the level of MxA expression in muscle cells is low in
both MxA-transgenic founder lines, G and L (29), as well as in
MxA-transgenic IFNAR-12/2 mice. As shown in Fig. 4E and
6E MxA expression in the brain is not uniform and there are
cells expressing higher levels of MxA than others. Most likely,
the inhibition of virus replication is not complete in the pe-
riphery and, depending on the MxA expression levels at the
site of CNS entry, LACV might gradually overcome MxA-
mediated inhibition. In humans, most LACV infections follow
a subclinical course, which may be the result of the induction of
MxA expression, but nevertheless in a few cases acute enceph-
alitis is produced (4, 5). In view of the present findings it is
conceivable that the degree of clinical manifestations may de-
pend on the extent of IFN production and hence MxA expres-
sion during infection. In the few cases where acute illness is
observed, the inefficient induction of antiviral effector proteins
like MxA might allow uncontrolled LACV replication at the
site of primary infection followed by virus spread to the brain.
Furthermore, humans with genetic defects in IFN signalling or
the MxA gene may be predisposed towards LACV encephali-
tis. It would be interesting to determine the proper function of
IFN signalling and MxA in severe cases of acute LACV en-
cephalitis.
SFV, a member of the family Togaviridae, is so far the only
positive-stranded RNA virus which is affected by the antiviral
action of MxA (27). Here, we show that MxA is also able to
inhibit the multiplication of SFV in vivo. One hundred percent
of IFNAR-12/2 mice died upon infection, whereas only 60%
of MxA-transgenic IFNAR-12/2 mice succumbed. Further-
more, viral titers were lower in MxA-transgenic IFNAR-12/2
mice than in IFNAR-12/2 control mice. It should be empha-
sized that SFV was detectable in the brains of all MxA-trans-
genic animals analyzed. Obviously, MxA is not able to prevent
initial infection of the CNS. Rather, MxA appears to reduce
virus replication within the brain. The reason why some ani-
mals became progressively diseased after a few days and finally
succumbed remains elusive. The simplest explanation is that
SFV replication occurred initially in brain cells expressing low
levels of MxA. This may have led to greater virus loads in the
CNS, and gradually the MxA-mediated block of virus multi-
plication may have been overcome in an increasing number of
cells.
Our results demonstrate that MxA is able to protect trans-
genic animals against a number of viruses and conclusively
establish this protein as an important intracellular mediator of
the antiviral effects of IFN-a/b.
Progress in genetic engineering should allow us in the near
future to introduce genes like MxA into farm animals in order
to improve their disease resistance. A weak spot in the live
cycle of arthropod-borne pathogens is their transmission by
vectors. Therefore, some viruses could be controlled by MxA
even before humans or livestock get infected. In an attempt to
establish pathogen-derived resistance in arthropod vectors, the
multiplication of LACV was shown to be inhibited in mosqui-
toes that express genetic elements of the LACV genome (32).
An alternative strategy might be to use MxA for the generation
of LACV-resistant mosquitoes.
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